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Abstract 
Background 
The causal association of variant Creutzfeldt-Jakob disease (vCJD) with Bovine 
Spongiform Encephalopathy (BSE) has raised significant concerns for public health.  
Assays for vCJD infection are vital for the application of therapeutics, the screening of 
organ donations and to maintain a safe blood supply. Currently the best diagnostic tools 
for vCJD depend upon the detection of disease associated prion protein (PrPSc) which is 
distinguished from normal background PrP (PrPC) by proteinase K digestion which can 
also degrade up to 90% of the target antigen. 
 
Study Design and Methods 
A sandwich ELISA methodology was developed using unique antibodies for the 
detection of disease associated PrP in the absence of proteinase K pre-treatment.  In 
combination with immunoprecipitation the assay was optimised for the detection of 
pathogenic PrP in large volumes of whole blood. 
 
Results 
Optimisation of the assay allowed detection of 2 x 104 LD50 Units ml-1 spiked in whole 
blood.  Application of the assay to clinically relevant volumes enabled the detection of 
750 LD50 Units ml-1 in 8ml of whole blood. 
 
Conclusion  
By combining the use of a unique antibody which selectively immunoprecipitates PrPSc 
with glycoform restrictive antibodies we have developed a rapid assay for vCJD infection 
that does not require any PK pre-treatment to achieve high levels of specificity in whole 
human blood, the most challenging potential analyte. The sensitivity of detection of vCJD 
infection is greater than the equivalent of a >2.5 million-fold dilution of infected brain, 
providing a highly sensitive immunoassay compatible with blood screening. 
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Introduction 
Prion diseases are a group of fatal, infectious neurodegenerative diseases, which included 
bovine spongiform encephalopathy (BSE) in cattle, scrapie in sheep and Creutzfeldt-
Jakob disease (CJD) in humans1,2.  Classically, the crucial step in the transmission and 
propagation of prion diseases, according to the protein-only hypothesis3 is the conversion 
of the host’s normal, cellular form of the prion protein (PrPC), via a post-translational 
process to a protease resistant, aggregated form (PrPSc)4. Detection of disease-associated, 
abnormal forms of the prion protein such as PrPSc is the most widely used and specific 
criterion for the diagnosis of prion disease in humans and animals1,2. 
 
Historically, methods to detect and diagnose prion disease have required post-mortem 
examination of tissue and according to the World Health Organisation (WHO) diagnostic 
criteria for variant CJD (vCJD), disease can only be classified as ‘probable’ in the 
presence of significant neurological deficit and confirmed as definite by means of 
neuropathological examination using immunohistochemical staining5. Despite this the 
use of highly sensitive western blotting has allowed the analysis of the pattern of 
deposition of PrPSc in a wide variety of tissues from vCJD patients6 including tonsil tissue 
obtained at post-mortem and biopsy7. The use of tonsil biopsy to determine if PrPSc is 
present by western blotting coupled with immunohistochemistry has proved both 
sensitive and specific for vCJD8 and allows patient care plans to be established, patients 
and families to be counselled accordingly and appropriate infection control measures 
implemented9,10, albeit at a late stage in disease progression. 
 
The pre-clinical phase of vCJD is currently unidentifiable, ranging from years to several 
decades, and presents a substantial infection risk to others via blood transfusion products, 
tissue and organ transplantation and other iatrogenic routes such as medical and dental 
procedures with contaminated instruments.  Indeed blood transfusions have been shown 
to be an effective route of infection for BSE and scrapie in sheep11 and vCJD in 
humans12-14. The introduction of a sensitive and specific blood based molecular 
diagnostic test for prion disease will provide an immediate solution to all of these 
problems and will facilitate early disease diagnosis and entry into therapeutic trials. 
However, the detection of PrPSc in blood is considerably more challenging than in other 
tissues.  
 
Very little is known about the nature and distribution of abnormal PrP in blood. Estimates 
of titres vary widely but the levels of prion infectivity demonstrated in buffy coat 
fractions as well as plasma derived from rodent sources are low15, with as little as 10 
LD50 Units present in 1ml of whole blood. In addition to the extremely low concentration 
of disease associated PrP, the PrPC background is very high.  There is a dearth of 
information available about the biochemical nature of disease associated PrP in blood, in 
particular uncertainty remains about whether pathogenic PrP in blood is protease 
resistant. Evidence is accumulating that challenges the belief that all forms of disease-
associated PrP are resistant to proteolysis. Indeed, it has recently been shown that the 
majority of disease associated PrP may well be sensitive to proteolytic digestion with 
proteinase K (PK)16-21.  Therefore any blood based assay for disease-associated PrP must 
not only have high sensitivity but also be extremely specific for abnormal PrP against a 
large background excess of PrPC.  
 
Over the last decade several groups have developed a range of different approaches to the 
problem of blood-based diagnosis of prion diseases.  Protein Misfolding Cyclic 
Amplification (PMCA) is a technique which can amplify minute quantities of PrPSc to 
levels which can be detected by conventional methods22 such as western blotting or 
immunoassays (Enzyme-Linked ImmunoSorbent Assays (ELISA) or Conformation-
Dependent Immunoassay (CDI)16).  PMCA has been used to detect PrPSc in buffy coat 
fractions of rodent blood23,24. More recently, PK resistant PrP (PrPRES) was amplified 
from blood leukocyte preparations obtained from scrapie-infected sheep25.    Human 
platelet homogenates have been used in PMCA experiments as an alternative substrate to 
amplify PrPSc from variant and sporadic CJD brain homogenates26,27. Serial PMCA gave 
a 10,000 fold increase in sensitivity, resulting in the detection of 10ng of vCJD brain in a 
100 µl PMCA reaction27.  However, the authors report an acute compatibility issue 
between the seed/substrate PRNP condon 129 which remains to be overcome.  The 
technical limitations associated with PMCA, such as the timescales involved, substrate 
availability and suitability and increasing evidence for  the spontaneous generation of 
protease resistant PrP de novo25,28 mean that PMCA is unlikely to provide the sole 
technology for a prion blood screening assay. A modified PMCA approach using 
recombinant PrP as the substrate with agitation instead of sonication has been used to 
distinguish between normal and prion-infected cerebral spinal fluid (CSF) obtained from 
experimentally infected hamsters29.  Other approaches have included the use of ligands 
which specifically capture disease-associated PrPSc from blood fractions, thereby 
concentrating the aberrant PrP before detection by standard methods30-32. Immunoassays 
specific for aggregated PrP, which increase sensitivity by linking signal amplification 
with target amplification using a simplified PMCA like reaction, have also been 
developed33.   
 
We have determined to develop an immunoassay for disease-associated PrP that does not 
require depletion of PrPC by proteolysis with proteinase K and that can be applied to 
whole blood. Here, we report the development of a highly sensitive and selective assay 
for the detection of disease associated PrPSc from clinically relevant volumes of whole 
blood without the need for PK digestion.  We have screened a range of monoclonal 
antibodies that have been raised against recombinant PrP in PrP0/0 knockout mice34 for 
their effectiveness to distinguish between PrPSc and PrPC in the absence of PK treatment 
in a sandwich ELISA format.  Optimisation of the assay allowed the detection of disease 
associated, PK-resistant and sensitive PrP spiked into whole blood at the picogram level. 
Coupling of the sandwich ELISA to the selective immunoprecipitation of PrPSc by a 
novel monoclonal antibody (ICSM 33) which has selectivity for disease-associated 
isoforms of PrP from large volumes of whole blood (Jackson et al, Manuscript submitted) 
allowed the detection of vCJD brain homogenate spiked into whole human blood at a 
dilution of > 2.5 million fold of total brain. 
Materials and Methods 
Tissues samples 
Storage and biochemical analysis of human brain samples was performed with consent 
from relatives and with approval from the Local Research Ethics Committee of the 
Institute of Neurology/National Hospital for Neurology and Neurosurgery (London, 
U.K.). All procedures were carried out in a microbiological containment level III facility 
with strict adherence to safety protocols. Brain homogenates (10% w/v) from patients 
with neuropathologically confirmed vCJD and normal control brain homogenates were 
prepared in Dulbecco's PBS (DPBS) lacking Ca2+ or Mg2+ ions by serial passage through 
needles of decreasing diameter or the use of tissue grinders (Anachem)6,35. Normal brains 
from the outbred CD1 strain of wild-type mice, as well as brains from CD1 mice which 
were experimentally infected with the Rocky Mountain Laboratory (RML) strain of 
prions36, a mouse adapted prion strain isolated by serial passage from an original 
inoculum of sheep scrapie, were homogenized in DPBS lacking Ca2+ or Mg2+ ions by  the 
use of tissue grinders (Anachem) to give a final concentration of 10% (w/v). Tissue 
homogenates were stored as aliquots in eppenforf tubes at -80°C. Whole human blood 
was obtained from the National Blood service, UK. 
 
For clarity, all dilutions of infectious material will be quoted as the fold dilution of total 
brain or the concentration of infectious titre (LD50 Unit ml-1).  The intracerebral 
infectious prion titre of the 10% (w/v)  RML brain homogenate used was determined to 
be 108.3 LD50 Units ml-1 by serial dilution and bioassay21.  The precise infectious titre of 
vCJD brain is unknown.  Therefore we have made the assumption that vCJD has a similar 
prion titre to RML and have calculated dilutions accordingly.  The quantity of PrPSc 
found in terminal prion disease brain has been calculated as 7 µg of PrPSc per gram wet 
weight brain37 and we have used this estimation for all subsequent calculations. 
 
Screening for optimal monoclonal antibody pairs in sandwich ELISA 
CD1 and RML-infected brain homogenates were processed with or without Proteinase K 
digestion and in native and denatured conditions. Briefly, 10 µl aliquots of 10% (w/v) 
brain homogenate were treated with 1 µl of Benzonase (25 U/µl, Merck) for 10 minutes 
at 37oC with agitation at 750 rpm in a Thermomixer (Eppendorf).  PK digested samples 
were incubated at 100 µg/ml final concentration for 10 minutes at 55oC.  2 µl of 500 mM 
AEBSF (4-(2-Aminoethyl) benzenesulphonyl fluoride hydrochloride) were added to all 
samples.  For denatured samples, 10 µl of 2% (w/v) sodium dodecyl sulphate (SDS) was 
added and samples heated for 10 minutes at 100oC.  All samples were adjusted to 600 µl 
with IP buffer (50mM Tris/HCl, pH8.4, containing 2% v/v Triton X-100 (molecular 
biology grade, Sigma), 2% w/v sodium lauroylsarcosine (Calbiochem) and 2% w/v 
bovine serum albumin (Fraction V, protease free, Sigma–Aldrich)). Aliquots were 
transferred to high binding capacity microtitre plates (Microlon 96W, Greiner Bio-One) 
coated with 250 ng/well of immobilized anti-PrP monoclonal capture antibodies (ICSM 
3, 4, 6, 7, 10, 15, 19, 24, 26, 33, 37, 38, 41 and 42; D-Gen Ltd, London). After incubation 
at 37oC for 1 hour with constant agitation, wells were washed with 3×300µl of PBST 
(Phosphate Buffered Saline containing 0.05% Tween 20 (Sigma)) using an automated 
microplate washer and 100µl of PBS containing 1% v/v Tween-20 and 1µl/ml 
biotinylated anti-PrP monoclonal detection antibody ICSM 18 or 35 (D-Gen Ltd, 
London) added. After 1 hour at 37oC with constant agitation, wells were washed as 
detailed above and 100 µl of PBS containing 1% v/v Tween-20 and a 1:10,000 dilution of 
streptavidin–horseradish-peroxidase conjugate (Dako Cytomation) added. After 
incubation at 37oC for 30 min with constant agitation, wells were washed with 4×300 µl 
of PBST and developed with 50l/well 3,3′,5,5′-Tetramethylbenzidine (TMB, Sigma). 
The colorimetric reaction was stopped with addition of 50l/well 2M Hydrochloric Acid 
and absorbance measured at 450 nm in a Tecan SpectraFluor microplate reader. 
 
Optimised high sensitivity ICSM10 sandwich ELISA without PK digestion 
10 µl samples were treated with 1 µl of Benzonase (25U/μl, Merck) followed by 
Thermolysin digestion (10 µg/ml final concentration, BDH) at 50oC for 10 minutes with 
constant agitation and subsequent addition of 20 µl of Denaturation buffer (6M 
Guanidine Hydrochloride (GdHCl) in PBS containing 10mM EDTA and 1x Complete 
protease inhibitor cocktail (Roche)). Following incubation at room temperature for 10 
minutes IP buffer is added to a final volume of 200 µl.  Aliquots were transferred to high 
binding, black microtitre plates (Microlon 96W, Greiner Bio-One) containing 
immobilized ICSM10 (250ng/well).  Wells were washed and processed as described 
above.  Biotinylated ICSM35 was used as the detection antibody. Wells were developed 
with 100µl of QuantaBlu Fluorogenic Peroxidase Substrate (Pierce).  Fluorescence 
(λex=325nm, λem=425nm) was measured on a Tecan SpectraFluoro microplate reader. 
 
Immunoprecipitation and detection by high sensitivity ELISA of disease-associated 
prion protein from whole blood spiked with vCJD brain homogenate  
Whole blood (250 µl) was spiked with vCJD brain homogenate dilutions.  Equal volumes 
of 2 x concentration of IP buffer were added along with 25µl of ICSM33 conjugated 
magnetic beads (Talon Dyna beads, Invitrogen) and incubated overnight at 4oC in a 
rotator.  Beads were washed 4 x 1 ml with IP buffer, 4 x 1 ml PBS containing 2% v/v 
Tween-20 and 2% w/v NP40 and a final wash of 1 ml PBS. Beads were resuspended in 
10µl of PBS containing 10 µg/ml Thermolysin and incubated at 50oC for 10 minutes.  20 
µl of Denaturation buffer was added and following incubation at room temperature for 10 
minutes volumes were made up to 200 µl with IP buffer and analysed by ICSM10 
sandwich ELISA. 
 
For 8 ml whole blood samples, 8 ml of 2 x concentration IP buffer was added followed 
by Benzonase pre-treatment.  Samples were divided into 1 ml aliquots, ICSM33 coated 
magnetic beads added and incubated over night at 4oC in a rotator.  Beads were washed 
as described above, before being pooled for Thermolysin digestion and preparation for 
ELISA in a minimum volume. 
Results 
Screen for monoclonal capture antibodies which discriminate between PrPSc and PrPC 
in the absence of Proteinase K digestion.  
Brain homogenates from normal CD1 and RML infected CD1 mice, processed for 
ELISA analysis with and without PK digestion and in a native or SDS denatured state, 
were used to screen our library of anti-PrP monoclonal antibodies for capture antibodies 
which show increased binding affinity for PrPSc over PrPC. Biotinylated ICSM18 and 35 
(ICSM18B and ICSM35B) were tested as detection antibodies (data not shown).  Several 
antibodies were determined to have selectivity in their binding of PrPSc to PrPC 
independent of PK digestion.  However, ICSM10, used as the capture antibody in 
combination with the detection antibody ICSM35B provided the greatest discrimination 
between prion infected and uninfected brain homogenates following denaturation (Figure 
1). PK digestion reduced the detectable signal from RML homogenates by up to 58%, a 
finding consistent with recent reported loses of signal following PK digestion21.  ICSM10 
capture and ICSM35B detection sandwich ELISA was therefore chosen for further 
development and adaption to a blood based assay. 
 
Optimisation of ICSM 10 sandwich ELISA 
Optimisation of sensitivity is essential if the assay is to approach the required limits of 
detection for the discrimination of endogenous prion infected blood from normal 
samples. Switching to a fluorometric detection system gave a four fold increase in 
sensitivity, from 2 x 106 ID50 Units ml-1 to 5 x 105 ID50 Units ml-1 at a threshold of 3 
standard deviations above the CD1 controls (data not shown). 
 A further limiting factor in assaying for low abundance targets is the quantity of sample 
that can be analysed at any one time.  In this case the large volume of IP buffer required 
to dilute the SDS denaturant to a concentration below which it does not affect the 
antibody/antigen interaction was limiting.  We therefore explored the use of Guanidine 
Hydrocholoride as a denaturant.  Using increasing concentrations of GdHCl, with 
subsequent dilution with a volume of IP buffer equivalent to that for SDS samples we 
established that a concentration of 4M GdHCl was sufficient to produce a positive signal 
comparable to that previously obtained (Figure 2a).  Optimisation for denaturant dilution 
to prevent inhibition of the antigen/antibody interaction whilst maximising the quantity of 
antigen per well was performed (Figure 2b). A final concentration of 0.4 M GdHCl (in 
200 μl) proved optimal, resulting in a 3 fold increase in the RML to CD1 background 
signal ratio giving a 5 fold total increase in maximal signal over SDS denatured samples. 
 
Thermolysin pretreatment 
Thermolysin has recently been shown to completely digest PrPC in brain 
homogenates21,38 whilst leaving both PK-resistant and PK-sensitive forms of PrPSc intact. 
Consequently we examined Thermolysin digestion as a means to further reduce assay 
background while minimizing the digestion of protease sensitive forms of disease 
associated PrP.  Digestion with Thermolysin at a concentration of 10 µg/ml for 10 
minutes at 50oC give a marginal increase in assay sensitivity from 2.5 x 105 ID50 Units 
ml-1 equivalents per well to 1.25 x 105 ID50 Units ml-1 (Figures 2C & 2D).  In additional 
Thermolysin treatment significantly improved assay reliability and dose responses, 
facilitating the detection of less than 5 pg of PrPSc per well. These results were confirmed 
for vCJD by analysis of dilution series of vCJD brain homogenate (data not shown). 
 
Sensitivity of detection of vCJD spiked into whole blood 
Detection of PrPSc in whole blood poses a far more difficult challenge than detection 
from brain homogenate or clarified blood fractions.  However, whole blood has the 
advantage that it contains the total infectivity present within a sample.  Currently the 
most sensitive and commonly used method for the detection of PrPSc and the clinical 
diagnosis of vCJD is the selective precipitation of PrPSc with sodium phosphotungstic 
acid followed by PK digestion and western blotting which can reliable detect 4,000 LD50 
Units ml-1, equivalent to a 50,000 fold dilution of whole brain6. Serial dilution of vCJD 
brain homogenate into normal brain homogenate followed by spiking into whole human 
blood was used to determine the assay’s sensitivity (Figure 3).  Our optimised sandwich 
ELISA was shown to be able to detect PrPSc at a dilution of 2 x 104 LD50 Units ml-1 
(~700fg PrPSc) in a total volume of 10µl of whole blood. 
 
Immunoprecipitation and detection of vCJD spiked into whole blood  
To improve the sensitivity of our immunoassay for prion infection and approach 
detection at the concentrations of 10-100 LD50 Units ml-1 found in blood39 we require the 
ability to capture and enrich PrPSc from large volumes of whole blood, maximising the 
amount of antigen per tissue sample that is applied to the ELISA. Hence we have studied 
the possibility of coupling an immunoprecipitation (IP) step with our discriminatory, high 
sensitivity ELISA as outlined in Figure 4.  
 Characterization of the interactions of a particular antibody, ICSM33, with both PrPC and 
PrPSc have previously shown that the aggregated nature of PrPSc and other forms of 
abnormal PrP permit their isolation from PrPC by immunoprecipitation involving 
multivalent interactions (Jackson et al, Manuscript Submitted). Immunoprecipitation 
reactions with ICSM33 from 250 µl of whole blood spiked with 10% w/v vCJD brain 
homogenate were performed as a dilution series.  After Thermolysin digestion in situ, 
antigen was denatured and released from the beads by incubation in 4M GdHCl before 
detection by the sandwich ELISA (Figure 5A). The combined methodology could 
reliably detect 3,200 LD50 Units ml-1 in 250 µl of whole blood, equivalent of ~2.8 pg of 
PrPSc per assay well at a dilution of 150,000 fold. 
 
Due to the particularly low levels of PrPSc present in blood it is likely the assay would 
require the enrichment of PrPSc from larger, clinically accessible volumes of whole blood.  
To investigate the adaption of our assay to larger blood volumes we performed ICSM33 
immunoprecipitation reactions on volumes up to 8 ml of whole blood spiked with either 
normal or vCJD brain homogenate before detection in our sandwich ELISA (Figure 5B).  
The coupled assay was clearly able to distinguish between vCJD and normal spiked 
samples with a detection sensitivity of 21 pg of PrPSc in 8mls of whole blood, 
corresponding to detection at a concentration of 750 LD50 Units ml-1 or a > 2.5 million 
fold dilution of infected brain equivalents.  
Discussion 
In the years since the outbreak of BSE and the discovery of its link to vCJD35,40,41 our 
understanding of prion pathology and biology has increased enormously. Highly sensitive 
and accurate methods for the diagnostic assessment of post-mortem tissues have been 
developed.  Application of these approaches to the diagnosis of patient biopsy samples 
has also proved extremely successful8. Recent reports have indicated that tissues such as 
blood and urine may contain levels of infectivity much higher than previously expected42.  
In fact, current evidence suggests that blood transfusions may provide a particularly 
efficient route for prion infection11-14.  Taken together with data suggesting that 
subclinical or carrier states exist in these diseases43, transmission of vCJD via transfusion 
or other iatrogenic means becomes an issue of concern for public health. 
 
Due to the prolonged pre-clinical phase of vCJD the need for a rapid, molecular 
diagnostic test for prion infection using easily obtainable tissues or fluids is a strategic 
priority for UK, European and American public health bodies.  However, the strict 
requirements for such a test prove extremely difficult to achieve.  Firstly, the quantities of 
PrPSc, currently our best biomarker for prion infection, are likely to be extremely low in 
blood, particularly in comparison to the very high levels of PrPC found in blood fractions.  
There is also very little information available about the biochemical nature of the 
infectious agent in blood.  Evidence indicates that a large proportion of PrPSc found in 
blood may well be protease sensitive.  This means that Proteinase K digestion, the usual 
diagnostic method of distinguishing between PrPSc and PrPC, is likely to be of little use in 
a blood-based assay.  The low abundance of the marker for prion infection and high 
background mean that any diagnostic assay will be required to be exceptionally selective 
as well as highly sensitive.  This is underlined when considering the consequences of 
false positive tests.  If an assay with a false positive rate of just 0.5% was to be used to 
screen the 2 million blood donations given annual in the United Kingdom alone, it would 
result in 10,000 false positive tests.  This would potentially have a huge impact on 
healthcare as these donors would most likely require long term screening, counselling 
and would been seen as candidates for long term prophylactic treatments. 
 
With these challenges in mind many novel approaches to the detection of PrPSc in blood 
have been investigated including methods of amplifying the small quantities of PrPSc 
present in blood fractions23,24 or from less accessible tissues such as CSF29, to increasing 
the sensitivity and specificity of detection methods and techniques for enriching PrPSc 
from blood.  However, there are problems associated with all of the current techniques 
under investigation.  What is becoming clear is that a successful diagnostic test for pre-
clinical prion infection is more than likely to consist of a combination of approaches. 
 
We have used our large panel of anti-PrP monoclonal antibodies to screen for an antibody 
combination which can selectively distinguish prion infected brain homogenates from 
uninfected homogenates in a sandwich ELISA format.  The ICSM10 capture and 
ICSM35B detection combination was shown to be capable of selectively detecting PK 
sensitive as well as PK resistant PrPSc.  Optimisation of the assay allowed detection at a 
level of 2 x 104 LD50 Unit ml-1, analogous to detection at a dilution of 25, 000 fold. 
 
Coupling of the highly sensitive assay with the selective enrichment of PrPSc from whole 
blood by immunoprecipitation with ICSM 33 (Jackson et al, Manuscript Submitted) gave 
an increased detection of PrPSc at a dilution of vCJD of 150,000 fold.  We also present 
the first report of the detection of vCJD brain homogenate spiked into a clinically 
relevant volume of whole blood.  Our combined assay successfully detected vCJD brain 
homogenate spiked into 8 ml of whole blood at a dilution of > 2.5 million fold, 
equivalent to detecting 750 LD50 Units ml-1.  Despite being short of the 10 LD50 Unit ml-1 
target likely to be required for detection of PrPSc in whole blood it remains a significant 
improvement upon the detection limit of 50,000-fold currently available using the most 
sensitive methodology for detection of PrPSc in tissues and clinical diagnosis of vCJD 
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Figure Legends 
Figure 1.  Monoclonal antibody ICSM 10 can distinguish between uninfected and 
prion infected brain homogenates in the absence of PK digestion. 
RML-infected and uninfected normal control CD1 brain homogenates were analysed by 
ICSM 10 capture and ICSM35B detection sandwich ELISA both before and after PK 
digestion and in a native and SDS denatured state.  Effective discrimination was achieved 
between infected and control samples without the need for PK digestion. PK digestion 
reduced the observable RML signal by 58%.   
 
Figure 2.  Optimisation of ICSM10 capture/ICSM35B detection sandwich ELISA 
(A) Optimisation of denaturant concentration.  Samples were denatured in increasing 
concentration of GdHCl before application to the ELISA.  Samples were diluted to 600 µl 
with IP buffer and 50 µl aliquots analysed (n=6). Optimal signal to noise ratio was 
achieved at an initial denaturant concentration of 4M GdHCl, with overall signal levels 
equivalent to that achieved with SDS denaturation.  (B)  Samples were denatured at 4M 
GdHCl before dilution with increasing volumes of IP buffer.  50 µl aliquots per well were 
analysed (n=6).   Dilution to 0.4 M final denaturant gave the optimal signal to noise ratio 
and increased the positive RML signal output by 5 fold in comparison to SDS denatured 
antigen.  Assay sensitivity was doubled by the inclusion of a Thermolysin step, from a 
2,000 fold dilution of RML brain (2.5 x 105 LD50 Units ml-1) before treatment (C) to a 
4,000 fold dilution (1.25 x 105 LD50 Units ml-1) after digestion (D) with 0.1 µg/ml 
Thermolysin at 60oC for 10 minutes (n=6).  Cut off for detection is the mean CD1 signal 
plus 3 standard deviations and is shown as a dashed, horizontal line. 
 Figure 3.  Sensitivity of detection of vCJD spiked into whole blood 
10% w/v vCJD brain homogenate was serially diluted into 10% w/v normal brain 
homogenate and then 1μl spiked into 10 µl aliquots of normal whole human blood (n=3).  
Normal control brain homogenate was similarly diluted into 10µl of normal whole blood 
and 10 µl aliquots analysed.  All samples therefore contain a total of 1% w/v total brain 
homogenate.  After processing, aliquots of 50 µl per well were analysed on microtitre 
plates (n=3).  The equivalent of a 25,000 fold dilution of whole vCJD brain was 
detectable above the cut off threshold (20,000 LD50 Units ml-1). The cut off for detection 
is the mean CD1 signal plus 3 standard deviations and is shown as a dashed, horizontal 
line. 
 
Figure 4.  Strategy for coupled immunoprecipitation and high sensitivity ELISA 
assay 
Proposed assay for detection of PrPSc in clinical volumes of whole blood.  PrPSc is 
selectively captured by ICSM 33 coated magnetic beads. The beads are washed to 
remove unbound PrPC. Thermolysin treatment is performed while PrPSc is still bound to 
the beads to further reduce background. Antigen is eluted in denaturing conditions and 
applied to ICSM10 coated ELISA plates for detection. 
 
Figure 5.  Immunoprecipitation and detection of vCJD spiked into whole blood 
(A) 10% w/v vCJD brain homogenate was serially diluted into 10% w/v normal brain 
homogentate then spiked into 250 μl of normal whole human blood (n=3).  An equivalent 
volume of normal 10% w/v brain homogenate was spiked into whole blood as a control.  
ICSM 33 immunoprecipitation and ICSM 10 capture/ICSM 35B detection ELISA 
indicate that the coupled assay could detect a 150,000 fold dilution of vCJD brain 
(threshold is average of normal background plus 3 standard deviations), equivalent to 
3,200 LD50 Units ml-1.  (B) Normal and vCJD 10% w/v brain were spiked into 8 ml of 
normal whole human blood (n=3).  Detection of vCJD was possible at dilution of vCJD 
brain of 750  LD50 Units ml-1, equivalent to ~15 pg of PrPSc (cut off threshold is the 
Normal mean plus 3 standard deviations).  This represents detection of PrPSc at > 2.5 
million fold dilution.  
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